A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

Blackwell Publishing

Access to resources Recommend Favorite

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

By Blais Normand   Camidge D.   Jonker Derek   Soulières Denis   Laurie Scott   Diab Sami   Ruiz-Garcia Ana   Thall Aron   Zhang Ke   Chao Richard   Chow Laura  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1487-1498

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors

By Camacho Luis   Olson Jon   Tong William   Young Charles   Spriggs David   Malkin Mark  

Investigational New Drugs, Vol. 25, Iss. 2, 2007-04 ,pp. : 131-138

Springer Publishing Company

Access to resources Recommend Favorite

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors

By Traynor Anne   Gordon Michael   Alberti Dona   Mendelson David   Munsey Mark   Wilding George   Gammans Richard   Read William  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 509-515

Springer Publishing Company

Access to resources Recommend Favorite

A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus

By Zhao Kuai-le  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1585-1590

Springer Publishing Company

Access to resources Recommend Favorite